Zacks: Brokerages Anticipate Aptinyx Inc (NASDAQ:APTX) Will Post Quarterly Sales of $380,000.00

Brokerages forecast that Aptinyx Inc (NASDAQ:APTX) will report $380,000.00 in sales for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Aptinyx’s earnings, with the highest sales estimate coming in at $500,000.00 and the lowest estimate coming in at $150,000.00. Aptinyx reported sales of $940,000.00 during the same quarter last year, which indicates a negative year-over-year growth rate of 59.6%. The firm is scheduled to issue its next quarterly earnings report on Tuesday, November 10th.

According to Zacks, analysts expect that Aptinyx will report full year sales of $1.50 million for the current fiscal year, with estimates ranging from $1.31 million to $1.80 million. For the next fiscal year, analysts anticipate that the company will post sales of $0.00. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Aptinyx.

Aptinyx (NASDAQ:APTX) last issued its earnings results on Thursday, August 13th. The company reported ($0.27) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.01. Aptinyx had a negative net margin of 1,764.55% and a negative return on equity of 49.15%. The business had revenue of $0.49 million during the quarter, compared to analysts’ expectations of $0.84 million.

APTX has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. initiated coverage on shares of Aptinyx in a research report on Wednesday. They set a “neutral” rating for the company. William Blair reissued a “buy” rating on shares of Aptinyx in a research note on Thursday, October 1st. SunTrust Banks assumed coverage on shares of Aptinyx in a research note on Wednesday, July 1st. They issued a “buy” rating and a $15.00 price objective for the company. BMO Capital Markets reiterated a “buy” rating and issued a $13.00 price target on shares of Aptinyx in a research note on Friday, August 14th. Finally, Zacks Investment Research upgraded shares of Aptinyx from a “sell” rating to a “hold” rating in a research note on Monday, July 20th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $9.31.

Several institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp purchased a new position in Aptinyx in the 1st quarter worth approximately $89,000. Two Sigma Advisers LP boosted its stake in shares of Aptinyx by 22.0% during the 1st quarter. Two Sigma Advisers LP now owns 100,800 shares of the company’s stock valued at $218,000 after buying an additional 18,200 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Aptinyx by 1,271.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 205,886 shares of the company’s stock valued at $859,000 after buying an additional 190,878 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Aptinyx by 15.0% during the 1st quarter. BlackRock Inc. now owns 426,294 shares of the company’s stock valued at $922,000 after buying an additional 55,482 shares during the last quarter. Finally, New York State Common Retirement Fund purchased a new position in shares of Aptinyx during the 2nd quarter valued at approximately $98,000. Institutional investors and hedge funds own 59.26% of the company’s stock.

Aptinyx stock traded down $0.05 during midday trading on Tuesday, hitting $3.73. 63,036 shares of the stock were exchanged, compared to its average volume of 301,637. Aptinyx has a fifty-two week low of $1.60 and a fifty-two week high of $5.28. The stock has a market capitalization of $175.17 million, a price-to-earnings ratio of -2.55 and a beta of 1.21. The stock’s 50-day simple moving average is $3.39 and its 200 day simple moving average is $3.59.

Aptinyx Company Profile

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

Read More: Cash Flow Analysis in Stock Selection

Get a free copy of the Zacks research report on Aptinyx (APTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aptinyx (NASDAQ:APTX)

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.